Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice

Antibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, vaccine efficacy was 31% and the sole primary correlate of reduced risk was shown to be vigorous antibody response targeting the V1V2 region of HIV-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Hioe, Catarina E., Li, Guangming, Liu, Xiaomei, Tsahouridis, Ourania, He, Xiuting, Funaki, Masaya, Klingler, Jéromine, Tang, Alex F., Feyznezhad, Roya, Heindel, Daniel W., Wang, Xiao-Hong, Spencer, David A., Hu, Guangnan, Satija, Namita, Prévost, Jérémie, Finzi, Andrés, Hessell, Ann J., Wang, Shixia, Lu, Shan, Chen, Benjamin K., Zolla-Pazner, Susan, Upadhyay, Chitra, Alvarez, Raymond, Su, Lishan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765624/
https://www.ncbi.nlm.nih.gov/pubmed/34986207
http://dx.doi.org/10.1371/journal.ppat.1010183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765624/
https://www.ncbi.nlm.nih.gov/pubmed/34986207
http://dx.doi.org/10.1371/journal.ppat.1010183

Ejemplares similares